BioCentury | Apr 25, 2011
Company News

Sera Prognostics management update

...Hired: Mark Ostrowski as president and CEO, formerly senior VP of sales and marketing at Perlegen Sciences Inc....
BioCentury | May 10, 2010
Company News

Celera sales and marketing update

...rights to IP cover methods of genetic analysis to detect variants on the chromosome from Perlegen Sciences Inc....
...Last month, Genetic Technologies Ltd. (ASX:GTG; NASDAQ:GENE, Fitzroy, Australia) said it acquired essentially all of Perlegen's...
BioCentury | Apr 26, 2010
Company News

Genetic Technologies, Perlegen deal

...Genetic Technologies said it acquired essentially all of Perlegen's assets, including all rights related to Perlegen's...
...history to determine the patient's lifetime and five-year risk for developing the disease. Last year, Perlegen...
...mode. Perlegen could not be reached for comment. Genetic Technologies Ltd. (ASX:GTG; NASDAQ:GENE), Fitzroy, Australia Perlegen Sciences Inc....
BioCentury | Sep 28, 2009
Company News

Perlegen sales and marketing update

...price of the test is $577. Perlegen said it will be available nationwide by 1Q10. Perlegen Sciences Inc....
BioCentury | Apr 27, 2009
Company News

Celera, deCode, Perlegen deal

...testing services and to develop test kits for managing patients with cardiovascular disease and diabetes. Perlegen...
...is eligible for royalties. Celera Corp. (NASDAQ:CRA), Alameda, Calif. deCode genetics Inc. (NASDAQ:DCGN), Reykjavik, Iceland Perlegen Sciences Inc....
BioCentury | Apr 13, 2009
Finance

Ebb & Flow

...City and the C21 BioVentures conference in Napa, Calif. At Future Leaders, molecular diagnostics company Perlegen Sciences Inc....
...round. CEO Bryan Walser said this should be sufficient to take the company to breakeven. Perlegen...
BioCentury | Sep 22, 2008
Clinical News

Sequencing technology: Study started

...variants that alter the risk of developing breast cancer among those receiving hormone replacement therapy. Perlegen Sciences Inc....
BioCentury | Jul 28, 2008
Company News

Perlegen diagnostics, genomics news

...particular disease or indication area. Perlegen is developing diagnostics for breast cancer and cardiovascular indications. Perlegen Sciences Inc....
BioCentury | Feb 25, 2008
Company News

Perlegen, SC Liver Research Consortium deal

...The parties will use Perlegen's genotyping technologies to discover genetic variations that predict treatment response in...
...group of physicians that coordinates research sponsors with research sites to advance liver disease research. Perlegen Sciences Inc....
BioCentury | Dec 10, 2007
Product Development

PPAR vigilance

...safety monitoring Metabolex/J&J MBX-102 Selective PPAR gamma modulator Ph II/III [400] Placebo, active comparator Edema Perlegen/Mitsubishi...
Items per page:
1 - 10 of 131
BioCentury | Apr 25, 2011
Company News

Sera Prognostics management update

...Hired: Mark Ostrowski as president and CEO, formerly senior VP of sales and marketing at Perlegen Sciences Inc....
BioCentury | May 10, 2010
Company News

Celera sales and marketing update

...rights to IP cover methods of genetic analysis to detect variants on the chromosome from Perlegen Sciences Inc....
...Last month, Genetic Technologies Ltd. (ASX:GTG; NASDAQ:GENE, Fitzroy, Australia) said it acquired essentially all of Perlegen's...
BioCentury | Apr 26, 2010
Company News

Genetic Technologies, Perlegen deal

...Genetic Technologies said it acquired essentially all of Perlegen's assets, including all rights related to Perlegen's...
...history to determine the patient's lifetime and five-year risk for developing the disease. Last year, Perlegen...
...mode. Perlegen could not be reached for comment. Genetic Technologies Ltd. (ASX:GTG; NASDAQ:GENE), Fitzroy, Australia Perlegen Sciences Inc....
BioCentury | Sep 28, 2009
Company News

Perlegen sales and marketing update

...price of the test is $577. Perlegen said it will be available nationwide by 1Q10. Perlegen Sciences Inc....
BioCentury | Apr 27, 2009
Company News

Celera, deCode, Perlegen deal

...testing services and to develop test kits for managing patients with cardiovascular disease and diabetes. Perlegen...
...is eligible for royalties. Celera Corp. (NASDAQ:CRA), Alameda, Calif. deCode genetics Inc. (NASDAQ:DCGN), Reykjavik, Iceland Perlegen Sciences Inc....
BioCentury | Apr 13, 2009
Finance

Ebb & Flow

...City and the C21 BioVentures conference in Napa, Calif. At Future Leaders, molecular diagnostics company Perlegen Sciences Inc....
...round. CEO Bryan Walser said this should be sufficient to take the company to breakeven. Perlegen...
BioCentury | Sep 22, 2008
Clinical News

Sequencing technology: Study started

...variants that alter the risk of developing breast cancer among those receiving hormone replacement therapy. Perlegen Sciences Inc....
BioCentury | Jul 28, 2008
Company News

Perlegen diagnostics, genomics news

...particular disease or indication area. Perlegen is developing diagnostics for breast cancer and cardiovascular indications. Perlegen Sciences Inc....
BioCentury | Feb 25, 2008
Company News

Perlegen, SC Liver Research Consortium deal

...The parties will use Perlegen's genotyping technologies to discover genetic variations that predict treatment response in...
...group of physicians that coordinates research sponsors with research sites to advance liver disease research. Perlegen Sciences Inc....
BioCentury | Dec 10, 2007
Product Development

PPAR vigilance

...safety monitoring Metabolex/J&J MBX-102 Selective PPAR gamma modulator Ph II/III [400] Placebo, active comparator Edema Perlegen/Mitsubishi...
Items per page:
1 - 10 of 131